Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Blood (2025) 146 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2025-4066

Published: 2025

Journal Articles

Melphalan weight-based dosing in overweight and obese patients undergoing autologous transplant for multiple myeloma

Anmol Goyal, Daniel Cancilla, Wei Wei, Danielle Cenin, Faiz Anwer, Claudio Brunstein, Shahzad Raza, Louis Williams, Jack Khouri

Blood (2025) 146 (Supplement 1): 4033.

https://doi.org/10.1182/blood-2025-4033

Published: 2025

Journal Articles

Underexplored mutations in plasma cell myeloma

Kirti Arora, Diana Basali, Yasar Shad, Akriti Jain, Christy Samaras, Haleema Sadia Adil, Jason Valent, Louis Williams, Jack Khouri, Sandra Mazzoni, Faiz Anwer, Abhay Singh, Shahzad Raza

Blood (2025) 146 (Supplement 1): 4025.

https://doi.org/10.1182/blood-2025-4025

Published: 2025

Journal Articles

Therapeutic trade-offs between ide-cel and cilta-cel in RRMM: A meta-analytic comparison of efficacy and adverse events

Mobina Golmohammadi, Shahzad Raza, Doris Hansen, Sandra Mazzoni, Louis Williams, Kirti Arora, Haleema Sadia Adil, Faiz Anwer, Majid Jaberi

Blood (2025) 146 (Supplement 1): 7606.

https://doi.org/10.1182/blood-2025-7606

Published: 2025

Journal Articles

ER-resident chaperon protein disulfide isomerase PDIA1 inhibition restricts and eliminate aberrant plasma cells

Raziullah Khan, Anand Tiwari, Mamta Sumi, Yahan Zhang, Daniel Vail, Dongxu Jiang, Sandra Mazzoni, Louis Williams, Babal Jha

Blood (2025) 146 (Supplement 1): 7488.

https://doi.org/10.1182/blood-2025-7488

Published: 2025

Journal Articles

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Blood (2025) 146 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2025-2814

Published: 2025

Journal Articles

Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells

Yulia Shifrin, Asieh Alikhah, Zahabiya Husain, Jack Khouri, Louis Williams, Christy Samaras, Shahzad Raza, Faiz Answer, Jason Valent, Beth Faiman, Emmet Samsa, Jessica Jones, Kelly Shepperd, Sabine Mai, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2025-2217

Published: 2025

Journal Articles

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Jessica Colon-Franco, Sujata Patil, Megan Molnar, Allison Winter, Sandra Mazzoni, Robert Dean, Louis Williams, Aaron Gerds, John Molina, Shahzad Raza, Faiz Anwer, Deepa Jagadeesh, Betty K. Hamilton, Claudio Brunstein, Brian Hill, Paolo Caimi

Blood (2025) 146 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2025-2397

Published: 2025

Journal Articles

The molecular landscape of Waldenström macroglobulinemia identified using whole genome sequencing

Blood (2025) 146 (Supplement 1): 1770.

https://doi.org/10.1182/blood-2025-1770

Published: 2025

Journal Articles

Dysregulated proteasome proteostasis acts as a driver of light chain amyloidosis

Sandra Mazzoni, Babal Jha, Louis Williams, Jack Khouri, Christy Samaras, Shahzad Raza, Faiz Anwer, Jason Valent, Arda Durmaz, Yahan Zhang, Kacey O'Donnell

Blood (2025) 146 (Supplement 1): 7473.

https://doi.org/10.1182/blood-2025-7473

Published: 2025

Journal Articles

Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?

Kirti Arora, Rishi Chowdhary, Diana Basali, Christy Samaras, Akriti Jain, Deevyashali Parekh, Jason Valent, Jack Khouri, Louis Williams, Sandra Mazzoni, Abhay Singh, Faiz Anwer, Shahzad Raza

Blood (2025) 146 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2025-2248

Published: 2025

Journal Articles

Aberrant clonal plasma cells bypass the proteasome proteostasis by endoplasmic reticulum associated protein degradation

Yahan Zhang, Sandra Mazzoni, Arda Durmaz, Kacey O'Donnell, Christy Samaras, Faiz Anwer, Shahzad Raza, Jason Valent, Jack Khouri, Louis Williams, Babal Jha

Blood (2025) 146 (Supplement 1): 7476.

https://doi.org/10.1182/blood-2025-7476

Published: 2025

Journal Articles

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Blood (2025) 146 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2025-3970

Published: 2025

Journal Articles

Fat pad biopsy versus target organ biopsy in systemic AL amyloidosis detection

Kristina Nasr, Yan Zou, Shahzad Raza, Mazen Hanna, Jack Khouri, Jason Valent, Christy Samaras, Sandra Mazzoni, Cynthia Scott, Kimberly Hamilton, Saveta Mathur, Beth Faiman, Louis Williams, Faiz Anwer, Diana Basali

Blood (2025) 146 (Supplement 1): 3969.

https://doi.org/10.1182/blood-2025-3969

Published: 2025

Journal Articles

Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis

Vasil Mico, Raymond Comenzo, Shahzad Raza, Jason Valent, Faiz Anwer, Christy Samaras, Louis Williams, Jack Khouri, Xia Wu, Parva Bhatt, Andreas Klein, Joslyn Rudoni, Teresa Fogaren, Mikhaila Rice, Jonathan Kissam, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 3961.

https://doi.org/10.1182/blood-2025-3961

Published: 2025

Journal Articles

Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era

Abhishek Kataria, Mikhaila Rice, Wei Wei, Faiz Anwer, Paolo Caimi, Allison Winter, Robert Dean, Taylor Brooks, Joslyn Rudoni, Jack Khouri, Christy Samaras, Shahzad Raza, Sandra Mazzoni, Jason Valent, Brian Hill, Louis Williams, Deepa Jagadeesh

Blood (2025) 146 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2025-4601

Published: 2025

Journal Articles

Modeling discordant cardiac and renal recovery trajectories in AL amyloidosis using interpretable machine learning

John Hanna, Ran Zhao, Diana Basali, Shahzad Raza, Jack Khouri, Sandra Mazzoni, Christy Samaras, Beth Faiman, Ali Mehdi, Mazen Hanna, Faiz Anwer, Jason Valent, Louis Williams

Blood (2025) 146 (Supplement 1): 5743.

https://doi.org/10.1182/blood-2025-5743

Published: 2025

Journal Articles

Conditional progression free survival (PFS) in patients with multiple myeloma (MM) after upfront autologous stem cell transplantation (ASCT): A secondary CIBMTR analysis

Utkarsh Goel, Danai Dima, Mohamed Hashem, Kristina Nasr, Hossam M. Ali, Louis Williams, Sandra Mazzoni, Shahzad Raza, Faiz Anwer, Jack Khouri

Blood (2025) 146 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2025-5762

Published: 2025

Journal Articles

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Kelsey Pandrangi, Kristina Nasr, Sharan Jhaveri, Mikhaila Rice, Joslyn Rudoni, Louis Williams, Christy Samaras, John Molina, Betty K. Hamilton, Shahzad Raza, Faiz Anwer, Jason Valent, Claudio Brunstein, Brian Hill, Paolo Caimi, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 6376.

https://doi.org/10.1182/blood-2025-6376

Published: 2025

Journal Articles

Real-world outcomes with teclistamab in relapsed/refractory multiple myeloma and severe renal failure: A propensity matched multi-center retrospective study using trinetx database

Deevyashali Parekh, Beth Faiman, Sandra Mazzoni, Louis Williams, Jack Khouri, Hossam M. Ali, Utkarsh Goel, Jason Valent, Diana Basali, Christy Samaras, Tara Roy, Alexandra McDonald, Faiz Anwer, Majid Jaberi, Kirti Arora, Haleema Sadia Adil, Julie Bevacqua, Rahul Seth, Shahzad Raza

Blood (2025) 146 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2025-6372

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Melphalan weight-based dosing in overweight and obese patients undergoing autologous transplant for multiple myeloma

Underexplored mutations in plasma cell myeloma

Therapeutic trade-offs between ide-cel and cilta-cel in RRMM: A meta-analytic comparison of efficacy and adverse events

ER-resident chaperon protein disulfide isomerase PDIA1 inhibition restricts and eliminate aberrant plasma cells

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

The molecular landscape of Waldenström macroglobulinemia identified using whole genome sequencing

Dysregulated proteasome proteostasis acts as a driver of light chain amyloidosis

Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?

Aberrant clonal plasma cells bypass the proteasome proteostasis by endoplasmic reticulum associated protein degradation

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Fat pad biopsy versus target organ biopsy in systemic AL amyloidosis detection

Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis

Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era

Modeling discordant cardiac and renal recovery trajectories in AL amyloidosis using interpretable machine learning

Conditional progression free survival (PFS) in patients with multiple myeloma (MM) after upfront autologous stem cell transplantation (ASCT): A secondary CIBMTR analysis

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Real-world outcomes with teclistamab in relapsed/refractory multiple myeloma and severe renal failure: A propensity matched multi-center retrospective study using trinetx database

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only